Product Description
Hoffmann-La Roche is developing Dalcetrapib as a treatment for Atherosclerotic Disease. (Sourced from: https://clinicaltrials.gov/study/NCT01059682)
Mechanisms of Action: CETP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Acute Coronary Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| dal-GenE-2 | P3 |
Recruiting |
Acute Coronary Syndrome |
2027-08-01 |